Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

The conversation discusses making a RU58841 solution for hair loss prevention and includes personal experiences with using RU58841 and minoxidil for hair regrowth, with a mention of monitoring health effects.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

Pyrilutamide from RUdirect is discussed, with users sharing experiences and alternative sources like Koshinemall. Users mention using treatments like minoxidil, RU58841, and dutasteride for hair loss.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

A user discusses using a mixed solution with minoxidil 2%, hydrocortisone butyrate, and estrone in the morning, and considering adding 5% minoxidil at night. They also use Restax softgel but avoid finasteride.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

Using Minoxidil and Redensyl together for hair loss. Users discuss application timing and effectiveness.

The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.

User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

Hair loss discussion mentions using estrogen mixed with growth stimulants like oral minoxidil for scalp hair growth. Idea proposed for an artificial SARM-estrogen that only affects hair without body side effects.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A transwoman shared her 11-month progress using hormone replacement therapy (HRT), finasteride, and minoxidil, reporting significant hair regrowth and satisfaction with the results. The discussion included various perspectives on HRT, its effects on hair and sexual function, and personal experiences with similar treatments.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

RU58841 treatment for hair loss, comparing premixed solutions to powder form. Users prefer powder for cost-effectiveness and customization.

The user is using RU58841 twice daily, dutasteride 0.5mg every two days, dutasteride mesotherapy every three months, and 20mg oral minoxidil daily. Other users suggest this regimen is excessive and recommend adding microneedling and ketoconazole shampoo.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.